# Stryker Corp: overview

SYK · NYSE · CIK 310764 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/syk.md) · [Financials](/companies/syk/financials.md) · [Filings](/companies/syk/filings.md) · [Insiders](/companies/syk/insiders.md)

Latest reported revenue: [$6.59bn](/filings/0000310764-26-000050.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 31, 2026 (XBRL us-gaap:Revenues, accession 0000310764-26-000050).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [5,494](/filings/0000310764-26-000010.md) | [6,436](/filings/0000310764-26-000010.md) | [5,866](/filings/0000310764-26-000031.md) | [6,022](/filings/0000310764-26-000050.md) | [6,057](/filings/0000310764-26-000010.md) | [7,171](/filings/0000310764-26-000010.md) | [6,020](/filings/0000310764-26-000031.md) | [6,589](/filings/0000310764-26-000050.md) |
| Gross margin | % | [64.0%](/filings/0000310764-26-000010.md) | [64.9%](/filings/0000310764-26-000010.md) | [63.8%](/filings/0000310764-26-000031.md) | [63.8%](/filings/0000310764-26-000050.md) | [63.6%](/filings/0000310764-26-000010.md) | [64.5%](/filings/0000310764-26-000010.md) | [63.3%](/filings/0000310764-26-000031.md) | [68.3%](/filings/0000310764-26-000050.md) |
| Operating margin | % | [19.7%](/filings/0000310764-25-000129.md) | [9.0% d](/filings/0000310764-26-000010.md) | [14.3%](/filings/0000310764-26-000031.md) | [18.5%](/filings/0000310764-26-000050.md) | [18.7%](/filings/0000310764-25-000129.md) | [25.2% d](/filings/0000310764-26-000010.md) | [15.5%](/filings/0000310764-26-000031.md) | [25.2%](/filings/0000310764-26-000050.md) |
| Net margin | % | [15.2%](/filings/0000310764-26-000010.md) | [8.5%](/filings/0000310764-26-000010.md) | [11.1%](/filings/0000310764-26-000031.md) | [14.7%](/filings/0000310764-26-000050.md) | [14.2%](/filings/0000310764-26-000010.md) | [11.8%](/filings/0000310764-26-000010.md) | [12.4%](/filings/0000310764-26-000031.md) | [19.4%](/filings/0000310764-26-000050.md) |
| Diluted EPS | $ per share | [2.16](/filings/0000310764-26-000010.md) | [1.41](/filings/0000310764-26-000010.md) | [1.69](/filings/0000310764-26-000031.md) | [2.29](/filings/0000310764-26-000050.md) | [2.22](/filings/0000310764-26-000010.md) | [2.20](/filings/0000310764-26-000010.md) | [1.93](/filings/0000310764-26-000031.md) | [3.30](/filings/0000310764-26-000050.md) |
| Free cash flow | $m | [1,304 d](/filings/0000310764-25-000129.md) | [1,665 d](/filings/0000310764-26-000010.md) | [127](/filings/0000310764-26-000031.md) | [928 d](/filings/0000310764-26-000050.md) | [1,353 d](/filings/0000310764-25-000129.md) | [1,875 d](/filings/0000310764-26-000010.md) | [415](/filings/0000310764-26-000031.md) | [1,059 d](/filings/0000310764-26-000050.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [17.1](/filings/0000310764-24-000024.md) | [18.4](/filings/0000310764-25-000023.md) | [20.5](/filings/0000310764-26-000010.md) | [22.6](/filings/0000310764-26-000010.md) | [25.1](/filings/0000310764-26-000010.md) |
| Gross margin | % | [64.1%](/filings/0000310764-24-000024.md) | [62.8%](/filings/0000310764-25-000023.md) | [63.7%](/filings/0000310764-26-000010.md) | [63.9%](/filings/0000310764-26-000010.md) | [64.0%](/filings/0000310764-26-000010.md) |
| Operating margin | % | [15.1%](/filings/0000310764-24-000024.md) | [15.4%](/filings/0000310764-25-000023.md) | [19.0%](/filings/0000310764-26-000010.md) | [16.3%](/filings/0000310764-26-000010.md) | [19.5%](/filings/0000310764-26-000010.md) |
| Net margin | % | [11.7%](/filings/0000310764-24-000024.md) | [12.8%](/filings/0000310764-25-000023.md) | [15.4%](/filings/0000310764-26-000010.md) | [13.2%](/filings/0000310764-26-000010.md) | [12.9%](/filings/0000310764-26-000010.md) |
| Diluted EPS | $ per share | [5.21](/filings/0000310764-24-000024.md) | [6.17](/filings/0000310764-25-000023.md) | [8.25](/filings/0000310764-26-000010.md) | [7.76](/filings/0000310764-26-000010.md) | [8.40](/filings/0000310764-26-000010.md) |
| Free cash flow | $bn | [2.7](/filings/0000310764-24-000024.md) | [2.0](/filings/0000310764-25-000023.md) | [3.1](/filings/0000310764-26-000010.md) | [3.5](/filings/0000310764-26-000010.md) | [4.3](/filings/0000310764-26-000010.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/syk/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $8.63bn | 27,414,742 |  | Reduced −187,307 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $7.10bn | 22,536,843 |  | Added +153,662 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $5.71bn | 17,260,943 |  | Added +1,664,046 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $4.90bn | 15,532,565 |  | Added +183,400 |
| [GREENLEAF TRUST](/funds/1162170.md) | 2026-06-30 | $4.79bn | 15,228,545 |  | Reduced −709,525 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $2.57bn | 8,173,167 |  | Reduced −161,077 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $2.57bn | 8,167,185 |  | Added +45,478 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $2.45bn | 7,819,802 |  | Added +71,508 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $1.88bn | 5,960,732 |  | Reduced −336,823 |
| [ALLIANCEBERNSTEIN L.P.](/funds/1109448.md) | 2026-06-30 | $1.62bn | 4,927,021 |  | Reduced −1,125,968 |

## Recent filings

[All 2,290 filings](/companies/syk/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-30 | 11:08 ET | [10-Q](/filings/0000310764-26-000061.md) | Quarterly report, period 2026-09-30 | 0000310764-26-000061 |
| 2026-10-29 | 16:11 ET | [8-K](/filings/0000310764-26-000059.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000310764-26-000059 |
| 2026-10-06 | 08:08 ET | [8-K](/filings/0001193125-26-414956.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-414956 |
| 2026-07-31 | 11:41 ET | [10-Q](/filings/0000310764-26-000050.md) | Quarterly report, period 2026-06-30 | 0000310764-26-000050 |
| 2026-07-30 | 16:09 ET | [8-K](/filings/0000310764-26-000048.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000310764-26-000048 |
| 2026-06-26 | 15:45 ET | [8-K](/filings/0000310764-26-000041.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000310764-26-000041 |
| 2026-05-20 | 16:21 ET | [8-K](/filings/0001193125-26-232643.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-232643 |
| 2026-05-11 | 11:10 ET | [10-Q](/filings/0000310764-26-000031.md) | Quarterly report, period 2026-03-31 | 0000310764-26-000031 |
| 2026-05-08 | 13:02 ET | [8-K](/filings/0000310764-26-000029.md) | 5.07 Shareholder vote results | 0000310764-26-000029 |
| 2026-04-30 | 16:07 ET | [8-K](/filings/0000310764-26-000025.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000310764-26-000025 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000310764-26-000010.md), filed Feb 11, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, locked when the 8-K was accepted. It is scored when the 10-Q or 10-K is ingested. [See the target](/leagues/2026q3/targets/bbc42f20-15b5-4f8c-bfe7-f8c0d6c993f7)

## About the filer

- CIK: 310764
- Tickers: SYK
- Exchange: NYSE
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: MI
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 11:14 ET. No prices; not investment advice.